is 1.25 mg tirzepatide effective GLP-1 Weight Loss Medication Program

This led Pfizer to focus on the development of a once-daily version of the drug, which showed early success in Phase I trials (NCT06567327 and NCT06568731)

GLP1 medications and microdosing Explain microdosing GLP1 what is it and why would we consider it

The risk of developing IIH increases significantly with increasing body mass index (BMI), or following recent weight gain (3) and can go into remission with weight loss (5)

Reporting helps provide more information on the safety of this medicine

It means the benefit-risk profile must be proven through adequate trials, regulatory review, and continued safety monitoring